NVR Inc (NVE.DU)
| Previous close | 6,950.00 |
| Open | 6,900.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6,900.00 - 6,900.00 |
| 52-week range | 4,960.00 - 7,400.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
La Cité Development Signs Agreement with NVR Ryan Homes for Large-Scale Single-Family Home Ownership Development in West Baltimore
La Cité Development, a leading real estate development corporation announced today the signing of an agreement with NVR Ryan Homes, the nation's 4th largest homebuilding and mortgage banking company, to add 180-units of single-family homes to the $800M Center\West, a large-scale redevelopment of 32.94 acres in the Poppleton neighborhood of West Baltimore.
- PR Newswire
NVR, INC. ANNOUNCES FIRST QUARTER RESULTS
NVR, Inc. (NYSE: NVR), one of the nation's largest homebuilding and mortgage banking companies, announced net income for its first quarter ended March 31, 2024 of $394.3 million, or $116.41 per diluted share. Net income and diluted earnings per share for the first quarter ended March 31, 2024 increased 14% and 17%, respectively, when compared to 2023 first quarter net income of $344.4 million, or $99.89 per diluted share. Consolidated revenues for the first quarter of 2024 totaled $2.33 billion,
- PR Newswire
NVR, INC. ANNOUNCES SHARE REPURCHASE AUTHORIZATION
NVR, Inc. (NYSE: NVR) announced today that its Board of Directors has authorized the repurchase of up to an aggregate of $750 million of its outstanding common stock. The repurchase authorization does not have an expiration date. The purchases will occur from time to time in the open market and/or in privately negotiated transactions as market conditions permit. The Company indicated that the authorization is a continuation of the stock repurchase program that began in 1994 and is consistent wit
